JBC Origene Your Gene Company

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wakasugi, K.
Right arrow Articles by Schimmel, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wakasugi, K.
Right arrow Articles by Schimmel, P.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

J Biol Chem, Vol. 274, Issue 33, 23155-23159, August 13, 1999


Highly Differentiated Motifs Responsible for Two Cytokine Activities of a Split Human tRNA Synthetase*

Keisuke WakasugiDagger and Paul Schimmel§

From The Skaggs Institute for Chemical Biology, The Scripps Research Institute, La Jolla, California 92037

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

While native human tyrosyl-tRNA synthetase (TyrRS) is inactive as a cell-signaling molecule, it can be split into two distinct cytokines. The enzyme is secreted under apoptotic conditions in culture where it is cleaved into an N-terminal fragment that harbors the catalytic site and into a C-domain fragment found only in the mammalian enzymes. The N-terminal fragment is an interleukin-8 (IL-8)-like cytokine, whereas the released C-domain is an endothelial-monocyte-activating polypeptide II (EMAP II)-like cytokine. Although the IL-8-like activity of the N-fragment depends on an ELR motif found in alpha -chemokines and conserved among mammalian TyrRSs, here we show that a similar (NYR) motif in the context of a lower eukaryote TyrRS does not confer the IL8-like activity. We also show that a heptapeptide from the C-domain has EMAP II-like chemotaxis activity for mononuclear phagocytes and polymorphonuclear leukocytes. Eukaryote proteins other than human TyrRS that have EMAP II-like domains have variants of the heptapeptide motif. Peptides based on these sequences are inactive as cytokines. Thus, the cytokine activities of split human TyrRS depend on highly differentiated motifs that are idiosyncratic to the mammalian system.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Although aminoacyl-tRNA synthetases are key enzymes in protein biosynthesis that catalyze aminoacylation of their cognate tRNAs (1-4), we recently demonstrated that human tyrosyl-tRNA synthetase (TyrRS)1 has novel cytokine functions in addition to its role in protein synthesis (5). Under apoptotic conditions in culture, the full-length enzyme is secreted, where two distinct cytokines can be generated by an extracellular protease such as leukocyte elastase (5). While the full-length enzyme is inactive in assays for a variety of cytokine activities, the sequestered cytokines are released by splitting the native enzyme into N- and C-terminal halves (5). This finding established a link between protein synthesis and signal transduction.

The N-terminal fragment contains the Rossmann nucleotide binding fold characteristic of all class I aminoacyl-tRNA synthetases. It is almost the same molecular size as TyrRS from prokaryotes or lower eukaryotes (see Fig. 1A). This N-fragment of human TyrRS has the catalytic domain capable of aminoacylation of human tyrosine tRNA (5). Surprisingly, the N-fragment (human mini TyrRS) binds strongly to the interleukin-8 (IL-8) type A receptor and, like IL-8, functions as a chemoattractant for polymorphonuclear leukocytes (PMNs) (5).

The C-terminal fragment of human TyrRS has high sequence similarity to the mature form of a proinflammatory cytokine known as human endothelial-monocyte-activating polypeptide II (EMAP II) (6). The isolated C-domain of human TyrRS has potent chemotaxis activity for PMNs and mononuclear phagocytes (MPs), and stimulates production of myeloperoxidase, tumor necrosis factor-alpha , and tissue factor. These are the same activities found for mature EMAP II (5, 7, 8).

Aware that other proteins had some of the same sequences found in EMAP II and in human TyrRS, we wondered whether these proteins had any of the same cytokine activities. Alternatively, the sequences important for the cytokine activities of human TyrRS could have a different function in other proteins. In that case, the cytokine activities of human TyrRS might be viewed as highly differentiated adaptations of domains or motifs that are basic platforms for more than one kind of biological activity. For example, Saccharomyces cerevisiae TyrRS has an Asn-Tyr-Arg (NYR) motif similar to the Glu-Leu-Arg (ELR) sequence of human TyrRS and of alpha -chemokines like IL-8. The ELR motif is essential for the leukocyte chemoattractant activity of these proteins (5, 9, 10), and yet there is no obvious biological rationale why a yeast protein like S. cerevisiae TyrRS would have chemokine activity. Similarly, portions of S. cerevisiae Arc1p, bacterial, and Caenorhabditis elegans methionyl-tRNA synthetase (MetRS), and the beta -subunit of prokaryotic phenylalanyl-tRNA synthetase (PheRS) have high sequence similarity to parts of mature EMAP II (11-13). Here again, there is no obvious rationale for EMAP II-like activity in the organisms that host these proteins. With these considerations in mind, we tested the functional significance of the IL-8- or EMAP II-like motifs in these proteins with respect to their potential chemokine activities. The results obtained strengthened the concept that, despite similarities of the motifs in human TyrRS with those in other proteins, the cytokine activities themselves are highly specific to human TyrRS.

    MATERIALS AND METHODS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Preparation of Peptides and Proteins-- Custom syntheses of peptides, their high performance liquid chromatography purification, and their mass spectroscopic analyses were performed by Genosys Biotechnologies, Inc. (Woodlands, TX). Human mini TyrRS, S. cerevisiae TyrRS, and Escherichia coli TyrRS (with a C-terminal tag of six histidine residues) were overexpressed in E. coli strain BL 21 (DE 3) (Novagen, Madison, WI) by induction with isopropyl beta -D-thiogalactopyranoside for 4 h. Using the procedures described by Novagen, the proteins were purified on a nickel affinity column (His·BindTM resin; Novagen) from the supernatant of lysed cells. Endotoxin was removed from the protein solutions by phase separation using Triton X-114 (14, 15) and was determined to be < 0.01 endotoxin units/ml by a Limulus Amebocyte lysate gel-clot assay (E-ToxateTM; Sigma). Protein concentration was determined by the Bradford assay with bovine serum albumin as a standard (Bio-Rad, Hercules, CA).

Preparation of Polymorphonuclear Leukocytes (PMNs) and Mononuclear Phagocytes (MPs)-- Human PMNs and MPs were prepared from acid citrate dextrose-treated blood of normal healthy volunteers (7). Human PMNs were isolated from the blood by centrifugation (700 × g) over Histopaque 1077 and 1119 (Sigma). Fractions containing PMNs was exposed to NaCl (0.2%) for 30 s to lyse erythrocytes, restored to isotonicity immediately by adding NaCl (1.6%), and centrifuged for 10 min. The latter procedure was repeated twice. Human MPs were isolated by centrifugation on Histopaque 1077 (Sigma). The mononuclear fraction was obtained, washed twice in Hanks' balanced salt solution, resuspended in RPMI 1640 medium (Sigma) containing heat-inactivated fetal bovine serum (10%, Sigma), plated on tissue culture flasks, and incubated in a 6% CO2 incubator at 37 °C for 1-2 h (16). Nonadherent cells were removed by washing the flasks three times with Hanks' balanced salt solution, and adherent cells were harvested by incubation with calcium-magnesium free phosphate-buffered saline containing EDTA (2 mM) for 15 min at 4 °C, followed by extensive washing.

Chemotaxis Assays-- Cell migration of PMNs or MPs was performed in a microchemotaxis chamber ChemoTXTM (Neuro Probe, Gaithersburg, MD) containing polycarbonate filters (5-µm pores) without or with polyvinylpyrrolidone, respectively (5, 17). PMNs or MPs were suspended in RPMI 1640 medium containing heat-inactivated fetal bovine serum (1%), and 104 cells were added/well to the upper chamber. The chemotactic stimulus was placed in the lower chamber, and cells were allowed to migrate for 45 min (for PMNs) or 3 h (for MPs) at 37 °C in a 6% CO2 incubator. After incubation, nonmigrating cells were removed, membranes were fixed in methanol, and migrating cells were visualized with the HemacolorTM stain set (EM Diagnostic Systems, Gibbstown, NJ). Migrating cells were counted in high power fields (HPFs).

Chemokine Receptor Binding Assays-- Custom radioiodination of human mini TyrRS with 125I was performed by Research & Diagnostic Antibody, Inc. (Richmond, CA). PMNs (2 × 106 cells) in 120 µl of RPMI 1640 medium containing 20 mM Hepes (pH 7.4) and 10 mg/ml bovine serum albumin were incubated on ice for 2 h with 10 nM 125I-labeled human mini TyrRS (specific activity of ~60 Ci/mmol) in the absence or presence of a 200-fold molar excess of unlabeled TyrRSs. Cells were separated from unbound radioactivity by centrifugation at approximately 8000 × g for 2 min through 500 µl of a 10% sucrose/phosphate-buffered saline cushion. The supernatant was aspirated, and the cell sediment was resuspended by using EcoLite (ICN Biomedicals, Irvine, CA) and counted in a liquid scintillation counter.

Gel Filtration Chromatography-- Gel filtration was accomplished on a Superose 6 HR 10/30 FPLC column (Amersham Pharmacia Biotech). Gel filtration standard (Bio-Rad) that included thyroglobulin, bovine gamma globulin, chicken ovalbumin, equine myoglobin, and vitamin B-12 was used.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Test for Cytokine Activity of Non-human TyrRS-- Our previous results showed that the ELR motif of human mini TyrRS plays an important role in PMN receptor binding, as it does in alpha -chemokines (5). As shown in Fig. 1A, the critical ELR motif of alpha -chemokines like IL-8 is conserved among mammalian TyrRSs. The corresponding sequence element of S. cerevisiae or E. coli TyrRS is NYR or ETV, respectively. Previously we showed that E. coli TyrRS neither activated nor bound to the IL-8 receptors on PMNs (5). A non-human eukaryotic TyrRS was not tested.


View larger version (20K):
[in this window]
[in a new window]
 
Fig. 1.   Effect of some TyrRSs on PMN receptor binding and PMN migration. Panel A, schematic alignments of human mini TyrRSs with human full-length TyrRS (GenBankTM Data Bank accession number U89436), S. cerevisiae TyrRS (L12221), and E. coli TyrRS (J01719). The arrow shows the approximate PMN elastase cleavage site in human TyrRS (5). The location of CP1 (connective polypeptide 1 (48)) that splits the Rossmann nucleotide binding fold in TyrRS is indicated. Numbers on the right of the sequences correspond to the protein sizes. Partial alignments of bovine (AF087021), S. cerevisiae (L12221), Schizosaccharomyces pombe (AL031324), Pneumocystis carinii (20), E. coli (J01719), and B. stearothermophilus TyrRSs (J01546) corresponding to the ELR motif of human TyrRS are shown. Panel B, after incubation of PMNs with 125I-human mini TyrRS (10 nM) in the absence or presence of a 200-fold molar excess of unlabeled TyrRSs for 2 h, cells were separated from unbound radioactivity by centrifugation, and the cell sediment was resuspended and counted in a liquid scintillation counter. The maximal specific response represents 2000 cpm. The data represent mean values ± S.D. of three independent measurements. Previously reported (5) data of human mini and E. coli TyrRSs are included for comparative purpose. Panel C, each protein (1 nM) or medium alone was added to the lower compartments of chemotaxis chambers and PMNs (104 cells) were added to the upper compartments. Chambers were incubated for 45 min, and then migrating cells were counted in HPFs. Four measurements of PMN chemotaxis were done with each protein. Each determination was an average of nine HPF measurements. The error bars correspond to standard deviations of the four determinations. The data shown are representative of at least three independent experiments done in this way. Previously reported (5) data of human mini and E. coli TyrRSs are included for comparative purposes.

To delineate further the interaction of TyrRSs with PMNs, human mini TyrRS was radioiodinated to have a tracer for binding studies. Binding of human mini TyrRS for PMNs is strictly competitive with IL-8 (5). Binding occurs to the IL-8 type A receptor with a dissociation constant Kd of 8 nM (5). Incubation of 125I-mini TyrRS with PMNs led to dose-dependent specific binding at 4 °C (5). We confirmed by competitive binding studies that binding of 125I-mini TyrRS was inhibited by the presence of excess amounts of unlabeled mini TyrRS but not by excess amounts of E. coli TyrRS (Fig. 1B). S. cerevisiae TyrRS inhibited binding of 125I-mini TyrRS to PMNs (Fig. 1B). We estimate that the dissociation constant for S. cerevisiae TyrRS is not more than 200-fold higher than that for human mini TyrRS. These results showed that a lower eukaryotic but not a bacterial TyrRS can bind to the PMN receptor for human mini TyrRS.

To determine whether binding of S. cerevisiae TyrRS to PMNs was associated with cytokine activity, we also investigated the chemotaxis activities of human mini, S. cerevisiae, or E. coli TyrRS. As shown in Fig. 1C, incubation of PMNs with human mini TyrRS (1 nM) led to induction of PMN migration. In contrast, no chemotaxis was observed with either S. cerevisiae TyrRS or E. coli TyrRS (each at a concentration of 1 nM) (Fig. 1C). In addition to checking of the potential cytokine activity of S. cerevisiae TyrRS at a concentration of 1 nM, concentrations of 0.1, 10, 100, and 1000 nM were also tested. No significant chemotaxis was observed (data not shown). Thus, the binding of S. cerevisiae TyrRS to PMNs is not associated with a serendipitous cytokine function.

Dimeric Structure for Human Mini TyrRS-- Prokaryotic and lower eukaryotic TyrRSs form stable dimers (18-20). We considered the possibility that the cytokine activities of human mini TyrRS were because of it having a different oligomeric state from the prokaryotic or lower eukaryotic homologs. For example, the region of the ELR motif might be in a distinct conformation in a monomeric versus a dimeric form of the protein. To investigate the oligomeric state of mini TyrRS, we determined the molecular weight of mini TyrRS by gel filtration chromatography on a Superose 6 HR 10/30 column. As controls, we performed gel filtration of E. coli and S. cerevisiae TyrRSs. Human mini TyrRS eluted at the same position as the E. coli or S. cerevisiae TyrRS, with an estimated molecular weight of 90 kDa (data not shown). This value corresponds closely to that expected for the dimeric form (84 kDa).

Cytokine Activities of Peptides Derived from Domains Similar to the C-Domain of Human TyrRS-- A synthetic peptide comprising seven residues near the N terminus of human mature EMAP II (RIGRIIT) was shown previously to induce migration of PMNs and MPs (21). To gain further insight into the cytokine activity of the C-domain of human TyrRS, we used a sequence alignment to design the corresponding peptide (RVGKIIT) of the C-domain (Fig. 2A). This C-domain peptide from TyrRS induced the same PMN and MP migration as did the mature EMAP II peptide (Fig. 2B). The effect of the C-domain peptide from TyrRS on PMN and MP migration showed a dose-dependence similar to that of the mature EMAP II peptide (data not shown). Thus, the C-domain of TyrRS and mature EMAP II share similar peptide motifs for chemotaxis at the same positions in their respective sequences.


View larger version (33K):
[in this window]
[in a new window]
 
Fig. 2.   Effect of heptapeptides on PMN and MP migration. Panel A, schematic comparison of the domains homologous to the C-domain of human TyrRS. Alignments of human TyrRS (accession number U89436) with human EMAP II (U10117), C. elegans MetRS (Z73427), and S. cerevisiae Arc1p (X95481) are shown. Partial sequence alignments with the RIGRIIT motif of human EMAP II are listed. Peptides were synthesized based on the partial sequence alignments. A cysteine residue of the EMAP II peptide was replaced by an arginine to enhance peptide stability and solubility. (Previous experiments clarified that this substitution did not alter its biologic properties (21).) Panel B, induction of PMN and MP migration (white and gray bars, respectively). Each peptide (1 nM) or medium alone was added to the lower compartments of chemotaxis chambers, and PMNs or MPs (104 cells) were added to the upper compartments. Chambers were incubated for 45 min (for PMNs) or 3 h (for MPs), and then migrating cells were counted in HPF. Results of chemotaxis assays were analyzed as in Fig. 1C.

Portions of S. cerevisiae Arc1p and C. elegans MetRS have high sequence homology with the C-domain of human TyrRS (6, 11, 13). Accordingly, we prepared the RVGKIIT-like peptide of S. cerevisiae Arc1p (RVGFIQK) and of C. elegans MetRS (RVGRIIK). Neither peptide induced PMN or MP migration (Fig. 2B). Thus, highly specific peptide sequences are required for the cytokine activities of human mature EMAP II and the C-domain of human TyrRS.

    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Because many residues and motifs are conserved among eukaryotic TyrRSs that are not found in their prokaryotic counterparts (22, 23), the binding of S. cerevisiae TyrRS to PMNs could reflect its structural similarity to human mini TyrRS. One reason why S. cerevisiae TyrRS does not have IL8-like cytokine activity might be attributed to the variation (NYR) of the sequence of critical ELR motif. We showed previously that a simple ELR right-arrow ELQ change inactivated the IL8-like activity of human mini TyrRS (5). In this connection, it is also noteworthy that prokaryotic and eukaryote cytoplasmic TyrRSs cannot cross-aminoacylate their respective tyrosine tRNAs because of a sequence variation in a peptide motif that is needed for discrimination of a species-specific difference in their respective tRNA sequences (20, 24, 25). Thus, both cytokine and RNA-related activities of human TyrRS are sensitive to the most subtle sequence variations.

Human mini TyrRS differs in primary structure from more typical alpha -chemokines. For example, while mini TyrRS contains an ELR motif that is critical for receptor binding, this motif is at the middle of the Rossmann fold that forms the site for synthesis of tyrosyl-adenylate. In contrast, the ELR motif of alpha -chemokines is located near the N terminus. Also, whereas alpha -chemokines have conserved cysteines and a Cys-Xaa-Cys motif (where Xaa is any residue), mini TyrRS does not share the conserved residues. Despite these differences in primary structures, human mini TyrRS is predicted (based on the crystal structure of Bacillus stearothermophilus TyrRS (26)) to form the same six-stranded beta -sheet as the alpha -chemokines (Fig. 3). Moreover, the predicted location of the ELR motif of human mini TyrRS is close to that of the alpha -chemokines (Fig. 3).


View larger version (18K):
[in this window]
[in a new window]
 
Fig. 3.   Schematic comparison between human mini TyrRS and alpha -chemokines. Shown are schematic structures of alpha -chemokines (27, 28) and the subunit of homodimeric human mini TyrRS (predicted on the basis of the crystal structure of B. stearothermophilus TyrRS (26)). In this figure, C-terminal parts of human mini TyrRS and alpha -chemokines are omitted. The locations of beta -strands or ELR motifs are delineated with solid arrows or circles, respectively. In the dimeric structure of TyrRS, the second subunit would appear below the plane of the one shown and is related by a 2-fold axis (26).

Under the experimental conditions of NMR or x-ray analyses, native IL-8 is a dimer (27, 28). However, at physiologically more relevant concentrations, monomeric and dimeric forms of IL-8 are in equilibrium, with the monomer being the prevalent form (29, 30). Dimerization-deficient IL-8 analogues were engineered by chemical modification or by mutations of residues at the dimer interface (31-33). Their structural analyses clarified that the IL-8 monomers have the same tertiary folding as the dimer (32, 34). In addition, their functional analyses showed that the monomers have full cytokine activity in vitro and in vivo (31-33). On the other hand, to mimic the dimeric form of IL-8, cross-linked single-chain dimers were designed (35). The results of chemotaxis and receptor binding assays showed that the dissociation of the dimer is not required for the biological activities (35). Thus, dimerization of IL-8 introduces no structural constraints for its tertiary folding or activities. Similarly, the ELR motif needed for the IL8-like activity is accessible in the dimeric structure found here for human mini TyrRS.

A long N-terminal segment precedes the ELR region of mini TyrRS (5). The same extension occurs in the yeast and bacterial proteins studied here so that the presence or absence of this extension cannot explain the unique cytokine activity of human mini TyrRS. Many of the ELR-containing chemokines have an N-terminal extension that is cleaved away to activate the chemokine (36, 37). These N-terminal extensions may block access to the ELR motif, and it is for that reason that activation occurs upon removal of the extensions. However, as explained above, the N-terminal region of the structural model of mini TyrRS does not physically block the ELR motif so that this region should be accessible for cytokine activation. Consistent with this conclusion, Hölzer et al. prepared a fusion protein in which the N terminus of IL-8 was fused to a Fab fragment (38). This chimeric protein showed specific binding to the IL-8 receptor, induced IL-8-mediated chemotactic activity, and stimulated release of myeloperoxidase.

Some amino acid residues in peptides corresponding to the RVGKIIT motif from the C-domain of human TyrRS are highly conserved among other proteins of both prokaryotes and eukaryotes (Table I). However, in this work we showed that the heptapeptides derived from S. cerevisiae Arc1p or C. elegans MetRS did not have EMAP II-like cytokine activities. Thus, the EMAP II-like motif in these proteins may originally have been associated with another biological function. Because human EMAP II and S. cerevisiae Arc1p are known to bind to tRNA (11-13), the EMAP II-like motif may have been originally developed for RNA binding. The structure-specific tRNA binding activity of the EMAP II-like Trbp111 from Aquifex aeolicus is consistent with this possibility (39). A. aeolicus is considered in some analyses to be in a deeply branching family of organisms (40-42).

                              
View this table:
[in this window]
[in a new window]
 
Table I
Heptapeptide sequences from proteins homologous to the C-domain of human TyrRS and cytokine activities of several mature proteins and synthetic peptides
Amino acids that are identical to the corresponding residue in one of the mammalian proteins are marked in bold. The hamster and sheep p43 proteins are close homologs of or identical to EMAP II (12).

Our results suggest that eukaryotic TyrRSs had opportunities to gain "cytokine" functions throughout their long evolution, by the addition of an extra domain and by accumulation of mutations. It is worth noting that Neurospora crassa and Podospora anserina mitochondrial TyrRSs also have other functions, i.e. catalysis of RNA splicing (43, 44). These proteins contain appended domains at their N and C termini when compared with other mitochondrial TyrRSs, and these appended domains are important for splicing (45, 46). Thus, during the molecular evolution of aminoacyl-tRNA synthetases, attachment and removal of new domains might have occurred frequently as these ancient enzymes acquired novel functions (1, 47).

    FOOTNOTES

* This work was supported by Grant GM 23562 from the National Institutes of Health and by a grant from the National Foundation for Cancer Research.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger Recipient of a JSPS (Japan Society for the Promotion of Science) Postdoctoral Fellowship for Research Abroad.

§ To whom correspondence should be addressed: The Skaggs Institute for Chemical Biology, The Scripps Research Institute, Beckman Center, 10550 North Torrey Pines Rd., La Jolla, CA 92037. Tel.: 619-784-8970; Fax: 619-784-8990; E-mail: schimmel@scripps.edu.

    ABBREVIATIONS

The abbreviations used are: TyrRS, tyrosyl-tRNA synthetase; EMAP II, endothelial-monocyte-activating polypeptide II; IL-8, interleukin-8; PMN, polymorphonuclear leukocyte; MP, mononuclear phagocyte; MetRS, methionyl-tRNA synthetase; HPF, high power field.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

1. Schimmel, P. (1987) Annu. Rev. Biochem. 56, 125-158[Medline] [Order article via Infotrieve]
2. Mirande, M. (1991) Prog. Nucleic Acid Res. Mol. Biol. 40, 95-142[Medline] [Order article via Infotrieve]
3. Moras, D. (1992) Trends Biochem. Sci. 17, 159-164[CrossRef][Medline] [Order article via Infotrieve]
4. Schimmel, P. (1991) Trends Biochem. Sci. 16, 1-3[CrossRef][Medline] [Order article via Infotrieve]
5. Wakasugi, K., and Schimmel, P. (1999) Science 284, 147-151[Abstract/Free Full Text]
6. Kleeman, T. A., Wei, D., Simpson, K. L., and First, E. A. (1997) J. Biol. Chem. 272, 14420-14425[Abstract/Free Full Text]
7. Kao, J., Ryan, J., Brett, J., Chen, J., Shen, H., Fan, Y.-G., Godman, G., Familletti, P., Wang, F., Pan, Y.-C., Stern, D., and Clauss, M. (1992) J. Biol. Chem. 267, 20239-20247[Abstract/Free Full Text]
8. Kao, J., Houck, K., Fan, Y., Haehnel, I., Libutti, S. K., Kayton, M. L., Grikscheit, T., Chabot, J., Nowygrod, R., Greenberg, S., Kuang, W.-J., Leung, D. W., Hayward, J. R., Kisiel, W., Heath, M., Brett, J., and Stern, D. M. (1994) J. Biol. Chem. 269, 25106-25119[Abstract/Free Full Text]
9. Hébert, C. A., Vitangcol, R. V., and Baker, J. B. (1991) J. Biol. Chem. 266, 18989-18994[Abstract/Free Full Text]
10. Clark-Lewis, I., Dewald, B., Geiser, T., Moser, B., and Baggiolini, M. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 3574-3577[Abstract/Free Full Text]
11. Simos, G., Segref, A., Fasiolo, F., Hellmuth, K., Shevchenko, A., Mann, M., and Hurt, E. C. (1996) EMBO J. 15, 5437-5448[Medline] [Order article via Infotrieve]
12. Quevillon, S., Agou, F., Robinson, J.-C., and Mirande, M. (1997) J. Biol. Chem. 272, 32573-32579[Abstract/Free Full Text]
13. Simos, G., Sauer, A., Fasiolo, F., and Hurt, E. C. (1998) Mol. Cell 1, 235-242[CrossRef][Medline] [Order article via Infotrieve]
14. Aida, Y., and Pabst, M. J. (1990) J. Immunol. Methods 132, 191-195[CrossRef][Medline] [Order article via Infotrieve]
15. Liu, S., Tobias, R., Mcclure, S., Styba, G., Shi, Q., and Jackowski, G. (1997) Clin. Biochem. 30, 455-463[CrossRef][Medline] [Order article via Infotrieve]
16. Kumagai, K., Itoh, K., Hinuma, S., and Tada, M. (1979) J. Immunol. Methods 29, 17-25[CrossRef][Medline] [Order article via Infotrieve]
17. Falk, W., Goodwin, R. H., Jr., and Leonard, E. J. (1980) J. Immunol. Methods 33, 239-247[CrossRef][Medline] [Order article via Infotrieve]
18. Calendar, R., and Berg, P. (1966) Biochemistry 5, 1681-1690[CrossRef][Medline] [Order article via Infotrieve]
19. Faulhammer, H. G., and Cramer, F. (1977) Eur. J. Biochem. 75, 561-570[Medline] [Order article via Infotrieve]
20. Quinn, C. L., Tao, N., and Schimmel, P. (1995) Biochemistry 34, 12489-12495[CrossRef][Medline] [Order article via Infotrieve]
21. Kao, J., Fan, Y.-G., Haehnel, I., Brett, J., Greenberg, S., Clauss, M., Kayton, M., Houck, K., Kisiel, W., Seljelid, R., Burnier, J., and Stern, D. (1994) J. Biol. Chem. 269, 9774-9782[Abstract/Free Full Text]
22. Ribas de Pouplana, L., Frugier, M., Quinn, C. L., and Schimmel, P. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 166-170[Abstract/Free Full Text]
23. Brown, J. R., Robb, F. T., Weiss, R., and Doolittle, W. F. (1997) J. Mol. Evol. 45, 9-16[CrossRef][Medline] [Order article via Infotrieve]
24. Chow, C. M., and RajBhandary, U. L. (1993) J. Biol. Chem. 268, 12855-12863[Abstract/Free Full Text]
25. Wakasugi, K., Quinn, C. L., Tao, N., and Schimmel, P. (1998) EMBO J. 17, 297-305[CrossRef][Medline] [Order article via Infotrieve]
26. Brick, P., Bhat, T. N., and Blow, D. M. (1989) J. Mol. Biol. 208, 83-98[CrossRef][Medline] [Order article via Infotrieve]
27. Baldwin, E. T., Weber, I. T., St. Charles, R., Xuan, J.-C., Appella, E., Yamada, M., Matsushima, K., Edwards, B. F. P., Clore, G. M., Gronenborn, A. M., and Wlodawer, A. (1991) Proc. Natl. Acad. Sci. U. S. A. 88, 502-506[Abstract/Free Full Text]
28. Clore, G. M., and Gronenborn, A. M. (1991) J. Mol. Biol. 217, 611-620[CrossRef][Medline] [Order article via Infotrieve]
29. Burrows, S. D., Doyle, M. L., Murphy, K. P., Franklin, S. G., White, J. R., Brooks, I., McNulty, D. E., Scott, M. O., Knutson, J. R., Porter, D., Young, P. R., and Hensley, P. (1994) Biochemistry 33, 12741-12745[CrossRef][Medline] [Order article via Infotrieve]
30. Paolini, J. F., Willard, D., Consler, T., Luther, M., and Krangel, K. S. (1994) J. Immunol. 153, 2704-2717[Abstract]
31. Rajarathnam, K., Sykes, B. D., Kay, C. M., Dewald, B., Geiser, T., Baggiolini, M., and Clark-Lewis, I. (1994) Science 264, 90-92[Abstract/Free Full Text]
32. Lowman, H. B., Fairbrother, W. J., Slagle, P. H., Kabakoff, R., Liu, J., Shire, S., and Hébert, C. A. (1997) Protein Sci. 6, 598-608[Abstract]
33. Horcher, M., Rot, A., Aschauer, H., and Besemer, J. (1998) Cytokine 10, 1-12[CrossRef][Medline] [Order article via Infotrieve]
34. Rajarathnam, K., Clark-Lewis, I., and Sykes, B. D. (1995) Biochemistry 34, 12983-12990[CrossRef][Medline] [Order article via Infotrieve]
35. Leong, S. R., Lowman, H. B., Liu, J., Shire, S., Deforge, L. E., Gillece-Castro, B. L., McDowell, R., and Hébert, C. A. (1997) Protein Sci. 6, 609-617[Abstract]
36. Walz, A., and Baggiolini, M. (1990) J. Exp. Med. 171, 449-454[Abstract/Free Full Text]
37. Brandt, E., Van Damme, J., and Flad, H.-D. (1991) Cytokine 3, 311-321[CrossRef][Medline] [Order article via Infotrieve]
38. Hölzer, W., Petersen, F., Strittmatter, W., Matzku, S., and von Hoegen, I. (1996) Cytokine 8, 214-221[CrossRef][Medline] [Order article via Infotrieve]
39. Morales, A. J., Swairjo, M., and Schimmel, P. (1999) EMBO J. 18, 3475-3483[CrossRef][Medline] [Order article via Infotrieve]
40. Pitulle, C., Yang, Y., Marchiani, M., Moore, E. R., Siefert, J. L., Aragno, M., Jurtshuk, P., Jr., and Fox, G. E. (1994) Int. J. Syst. Bacteriol. 44, 620-626[Abstract/Free Full Text]
41. Brown, J. R., and Doolittle, W. F. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 2441-2445[Abstract/Free Full Text]
42. Bocchetta, M., Huber, R., and Cammarano, P. (1996) J. Bacteriol. 178, 1762-1765[Abstract/Free Full Text]
43. Akins, R. A., and Lambowitz, A. M. (1987) Cell 50, 331-345[CrossRef][Medline] [Order article via Infotrieve]
44. Kämper, U., Kück, U., Cherniack, A. D., and Lambowitz, A. M. (1992) Mol. Cell. Biol. 12, 499-511[Abstract/Free Full Text]
45. Cherniack, A. D., Garriga, G., Kittle, J. D. J., Akins, R. A., and Lambowitz, A. M. (1990) Cell 62, 745-755[CrossRef][Medline] [Order article via Infotrieve]
46. Kittle, J. D. J., Mohr, G., Gianelos, J. A., Wang, H., and Lambowitz, A. M. (1991) Genes Dev. 5, 1009-1021[Abstract/Free Full Text]
47. Giegé, R., Puglisi, J. D., and Florentz, C. (1993) Prog. Nucleic Acids Res. Mol. Biol. 45, 129-206[Medline] [Order article via Infotrieve]
48. Starzyk, R. M., Webster, T. A., and Schimmel, P. (1987) Science 237, 1614-1618[Abstract/Free Full Text]
49. Tas, M. P., Houghton, J., Jakobsen, A. M., Tolmachova, T., Carmichael, J., and Murray, J. C. (1997) Cytokine 9, 535-539[CrossRef][Medline] [Order article via Infotrieve]


Copyright © 1999 by The American Society for Biochemistry and Molecular Biology, Inc.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
FASEB J.Home page
Y. Greenberg, M. King, W. B. Kiosses, K. Ewalt, X. Yang, P. Schimmel, J. S. Reader, and E. Tzima
The novel fragment of tyrosyl tRNA synthetase, mini-TyrRS, is secreted to induce an angiogenic response in endothelial cells
FASEB J, May 1, 2008; 22(5): 1597 - 1605.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
C. Peter, M. Waibel, C. G. Radu, L. V. Yang, O. N. Witte, K. Schulze-Osthoff, S. Wesselborg, and K. Lauber
Migration to Apoptotic "Find-me" Signals Is Mediated via the Phagocyte Receptor G2A
J. Biol. Chem., February 29, 2008; 283(9): 5296 - 5305.
[Abstract] [Full Text] [PDF]


Home page
J. Leukoc. Biol.Home page
J. J. Oppenheim, H. F. Dong, P. Plotz, R. R. Caspi, M. Dykstra, S. Pierce, R. Martin, C. Carlos, O. Finn, O. Koul, et al.
Autoantigens act as tissue-specific chemoattractants
J. Leukoc. Biol., June 1, 2005; 77(6): 854 - 861.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
E. Tzima, J. S. Reader, M. Irani-Tehrani, K. L. Ewalt, M. A. Schwartz, and P. Schimmel
VE-cadherin Links tRNA Synthetase Cytokine to Anti-angiogenic Function
J. Biol. Chem., January 28, 2005; 280(4): 2405 - 2408.
[Abstract] [Full Text] [PDF]


Home page
J. Cell Sci.Home page
S. W. Lee, B. H. Cho, S. G. Park, and S. Kim
Aminoacyl-tRNA synthetase complexes: beyond translation
J. Cell Sci., September 1, 2004; 117(17): 3725 - 3734.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
S.-H. Kim, S. M. Lessner, Y. Sakurai, and Z. S. Galis
Cyclophilin A as a Novel Biphasic Mediator of Endothelial Activation and Dysfunction
Am. J. Pathol., May 1, 2004; 164(5): 1567 - 1574.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
K. Beebe, E. Merriman, L. R. de Pouplana, and P. Schimmel
A domain for editing by an archaebacterial tRNA synthetase
PNAS, April 20, 2004; 101(16): 5958 - 5963.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
E. Tzima, J. S. Reader, M. Irani-Tehrani, K. L. Ewalt, M. A. Schwartz, and P. Schimmel
Biologically active fragment of a human tRNA synthetase inhibits fluid shear stress-activated responses of endothelial cells
PNAS, December 9, 2003; 100(25): 14903 - 14907.
[Abstract] [Full Text] [PDF]


Home page
Hum Mol GenetHome page
O. Corti, C. Hampe, H. Koutnikova, F. Darios, S. Jacquier, A. Prigent, J.-C. Robinson, L. Pradier, M. Ruberg, M. Mirande, et al.
The p38 subunit of the aminoacyl-tRNA synthetase complex is a Parkin substrate: linking protein biosynthesis and neurodegeneration
Hum. Mol. Genet., June 15, 2003; 12(12): 1427 - 1437.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
X.-L. Yang, R. J. Skene, D. E. McRee, and P. Schimmel
Crystal structure of a human aminoacyl-tRNA synthetase cytokine
PNAS, November 26, 2002; 99(24): 15369 - 15374.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
S. G. Park, Y.-S. Kang, Y. H. Ahn, S. H. Lee, K.-R. Kim, K.-W. Kim, G. Y. Koh, Y.-G. Ko, and S. Kim
Dose-dependent Biphasic Activity of tRNA Synthetase-associating Factor, p43, in Angiogenesis
J. Biol. Chem., November 15, 2002; 277(47): 45243 - 45248.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
U. M. Nagarajan, A. Bushey, and J. M. Boss
Modulation of Gene Expression by the MHC Class II Transactivator
J. Immunol., November 1, 2002; 169(9): 5078 - 5088.
[Abstract] [Full Text] [PDF]


Home page
JEMHome page
O.M. Z. Howard, H. F. Dong, D. Yang, N. Raben, K. Nagaraju, A. Rosen, L. Casciola-Rosen, M. Hartlein, M. Kron, D. Yang, et al.
Histidyl-tRNA Synthetase and Asparaginyl-tRNA Synthetase, Autoantigens in Myositis, Activate Chemokine Receptors on T Lymphocytes and Immature Dendritic Cells
J. Exp. Med., September 16, 2002; 196(6): 781 - 791.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
K. Wakasugi, B. M. Slike, J. Hood, K. L. Ewalt, D. A. Cheresh, and P. Schimmel
Induction of Angiogenesis by a Fragment of Human Tyrosyl-tRNA Synthetase
J. Biol. Chem., May 31, 2002; 277(23): 20124 - 20126.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
J. Austin and E. A. First
Catalysis of Tyrosyl-Adenylate Formation by the Human Tyrosyl-tRNA Synthetase
J. Biol. Chem., April 19, 2002; 277(17): 14812 - 14820.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
B. A. Steer and P. Schimmel
Domain-domain communication in a miniature archaebacterial tRNA synthetase
PNAS, November 23, 1999; 96(24): 13644 - 13649.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
Y. Kim, J. Shin, R. Li, C. Cheong, K. Kim, and S. Kim
A Novel Anti-tumor Cytokine Contains an RNA Binding Motif Present in Aminoacyl-tRNA Synthetases
J. Biol. Chem., August 25, 2000; 275(35): 27062 - 27068.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
Y.-G. Ko, E.-K. Kim, T. Kim, H. Park, H.-S. Park, E.-J. Choi, and S. Kim
Glutamine-dependent Antiapoptotic Interaction of Human Glutaminyl-tRNA Synthetase with Apoptosis Signal-regulating Kinase 1
J. Biol. Chem., February 16, 2001; 276(8): 6030 - 6036.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
R. Hammamieh and D. C. H. Yang
Magnesium Ion-mediated Binding to tRNA by an